Skip to content
Search

Latest Stories

Community pharmacy teams urged to support safety study of Oxford/AZ vaccine

Community pharmacy teams have being asked to support a safety study of the new Oxford/AstraZeneca Covid-19 vaccine to ensure any side effects are quickly recognised and acted upon.

The Drug Safety Research Unit (DSRU) in Southampton is monitoring the safety of the vaccine by proactively collecting near 'real-time' data from patients receiving the vaccine.


The DSRU will enrol at least 10,000 patients who will be contacted at regular intervals after receiving the Oxford/AstraZeneca vaccine, and asked whether they are experiencing any possible side effects.

The study is one element of a series of measures to help protect the public.

Commenting on the start of the study, Professor Saad Shakir, DSRU director, said: “Doctors, nurses, pharmacists, healthcare assistants and all other health professionals already understand only too well the impact Covid-19 has on patients and their loved-ones, so we hope they will also understand how crucial it is that we monitor new vaccines and treatments so they are as safe and effective as possible.

“We are urging all healthcare professionals to gently encourage patients having the Oxford/AstraZeneca vaccine to sign up for our study. For patients, it’s only a few short questionnaires. But their contribution can play a huge part in our collective efforts to protect people from such a devastating disease.”

Pharmacy team members can sign up for the study themselves if they have had the Oxford/AZ vaccine.

Additionally, pharmacy teams can encourage their patients who have received the Oxford/AZ vaccine to participate in the study.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less